EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 9th, 2017 • Monopar Therapeutics • Illinois
This Executive Employment Agreement (the “Agreement”) is entered into as of November 1, 2017, by and between Kim R. Tsuchimoto (“Executive”) and Monopar Therapeutics Inc. (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • November 9th, 2017 • Monopar Therapeutics • Illinois
This Executive Employment Agreement (the "Agreement") is entered into as of January 1, 2017, by and between Chandler D. Robinson ("Executive") and Monopar Therapeutics Inc. (the "Company").
CONTRIBUTION AGREEMENT (351)Contribution Agreement • November 9th, 2017 • Monopar Therapeutics • Delaware
This Contribution Agreement (this “Agreement”) is entered into as of August 25, 2017 (the “Effective Date”), among TacticGem LLC, a Delaware limited liability company (the “Company”), Monopar Therapeutics Inc., a Delaware corporation (“Monopar”), Gem Pharmaceuticals, LLC, an Alabama limited liability company (“Gem”) and Tactic Pharma, LLC, an Illinois limited liability company (“Tactic”, and collectively with Gem, the owners of 100% of the issued and outstanding limited liability company interests of the Company). The Company, Monopar, Tactic, and Gem are sometimes hereinafter referred to collectively as the “Parties”, and each individually as a “Party”.
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • November 9th, 2017 • Monopar Therapeutics • New York
THIS AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”), effective as of September 24, 2014 (the “Effective Date”), is entered into between Tactic Pharma, LLC, a limited liability company (“TACTIC”), having offices at 1062 Princeton Avenue, Highland Park, IL 60035 and XOMA (US) LLC, a Delaware limited liability company (“XOMA”), having offices at 2910 Seventh Street, Berkeley, California 94710. Each of XOMA and TACTIC are sometimes referred to herein separately as a “Party” and together as “Parties.”
CANCER RESEARCH UK and CANCER RESEARCH TECHNOLOGY LIMITED and MONOPAR THERAPEUTICS LLC CLINICAL TRIAL AND OPTION AGREEMENT (CTOA)Clinical Trial and Option Agreement • November 9th, 2017 • Monopar Therapeutics
Schedule 1 Company Patent Rights Schedule 2 Report Synopsis Headings Schedule 3 Licence from CRT to Company Schedule 4 No Fault Compensation Scheme Schedule 5 Assignment and Licence from Company to CRT Schedule 6 Protocol Schedule 7 Company Materials Schedule 8 Back-Up Antibodies Schedule 9 XOMA Licence Schedule 10 Progress Reports Schedule 11 Clinical Protocol Summary Schedule 12 Escrow Agreement Schedule 13 Technical Agreement
CONSULTING AGREEMENTConsulting Agreement • November 9th, 2017 • Monopar Therapeutics • Illinois
This Consulting Agreement (herein referred to as "'Agreement'') is made and entered into as of this December 15, 2016 (the "Effective Date"), by and between Monopar Therapeutics, Inc. (herein referred to as "Monopar'·). a Delaware corporation, located at 5 Revere Dr., Suite 200, Northbrook, IL 60062, and pRx Consulting, LLC (herein referred to as pRx), a Delaware corporation located at # (each herein referred to as 'Party' and collectively as "Parties'').
VALIDIVE® OPTION AND LICENSE AGREEMENT BY AND BETWEEN MONOPAR THERAPEUTICS INC. AND ONXEO S.A.License Agreement • November 9th, 2017 • Monopar Therapeutics • New York
THIS OPTION AND LICENSE AGREEMENT (together with any Schedules attached hereto, this “Agreement”) is made and entered into as of June 17, 2016 (the “Effective Date”), by and between Monopar Therapeutics Inc., a Delaware corporation located at 598 Rockefeller Rd, Lake Forest, Illinois 60201, United States of America (“Monopar”), and Onxeo S.A., a French société anonyme à Conseil d’administration located at 49, boulevard du Général Martial Valin, 75015 Paris, France (“Onxeo”). Monopar and Onxeo are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CONSULTING AGREEMENTConsulting Agreement • November 9th, 2017 • Monopar Therapeutics • Illinois
This Consulting Agreement (herein referred to as "Agreement") is made and entered into as of this December 15, 2016 (the "Effective Date"), by and between Monopar Therapeutics Inc. (herein referred to as "Monopar"), a Delaware limited liability corporation, located at corporation, located at 5 Revere Dr., Suite 200, Northbrook, IL 60062, and Kim.R. Tsuchimoto (herein referred to as "TSUCHIMOTO") who resides at # (each herein referred to as "Party" and collectively as "Parties").
